Hudson Heights Innovations: Columbia | Deerfield

Hudson Heights Innovations is a collaboration between Columbia University and Deerfield Management to advance the translation of biomedical discoveries into transformative treatments for improved quality of life and cures for disease. Through this newly launched initiative, up to $130 million of initial funding will be made available to back the initiative over 10 years by Deerfield and its partners. In addition, Deerfield will provide development expertise in support of innovative drug research across a span of high-need therapeutic areas, as well as those targeting patients who suffer from hard-to-treat and rare diseases.

Hudson Heights is currently requesting proposals to develop innovative therapeutic strategies to treat rare genetic diseases. Proposals are due by February 26th, 2021.

  • Disorders or conditions with a prevalence of fewer than 200,000 people in the U.S. are considered rare diseases. All rare diseases with a known genetic cause that can be diagnosed with the aid of clinical sequencing are eligible. Preference is given to diseases with existing patient communities and clear clinical measures.
  • Each therapeutic discovery project supported by this funding opportunity must focus on a clear therapeutic hypothesis enabled by genetic and biological understanding of disease pathophysiology with cellular and in vivo models available. Existing therapeutic candidates are not required.
  • Therapeutics of interest include small molecules, biopharmaceuticals, and gene therapies.

Interested faculty should email Sam Galindo (s.galindo@columbia.edu) for next steps and formal submission

To learn more about Hudson Heights Innovations please create a profile by clicking here.

HHI RFP

About Hudson Heights Innovations

On June 5th 2019 Columbia University and Deerfield Management announced the creation of a major research and development alliance. The collaboration is intended to advance the translation of biomedical discoveries into transformative treatments for improved quality of life and cures for disease.

Through a newly launched company called Hudson Heights Innovations, up to $130 million of initial funding will be made available to back the initiative over 10 years by Deerfield and its partners. In addition, Deerfield will provide development expertise in support of innovative drug research across a span of high-need therapeutic areas, as well as those targeting patients who suffer from hard-to-treat and rare diseases.